Viridian Gains FDA Nod for Lumvoa, Threatens Amgen's Tepezza Market
AMGN•Viridian Therapeutics received FDA approval for its TED treatment Lumvoa (veligrotug-vvze), setting up direct competition with Amgen's Tepezza. The new entrant could erode Tepezza's market share in a thyroid eye disease market previously dominated by Amgen, introducing pricing and volume pressures.
1. Viridian Secures FDA Approval for Lumvoa
Viridian Therapeutics won FDA approval for Lumvoa (veligrotug-vvze) as a treatment for thyroid eye disease, marking its first commercial drug and entry into a market long dominated by a single product.
2. Competitive Pressure on Amgen's Tepezza
Lumvoa's launch creates direct head-to-head competition with Amgen's Tepezza, risking a shift in patient and payer preferences and potential downward pressure on Tepezza pricing and volume.
